RP 1664
Alternative Names: RP-1664Latest Information Update: 07 Jul 2026
At a glance
- Originator Repare Therapeutics
- Class Amines; Antineoplastics; Cyclopropanes; Fluorocarbons; Imidazoles; Pyrazoles; Pyrimidinones; Small molecules; Sulfones
- Mechanism of Action PLK4 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Jul 2026 Chemical structure information added
- 28 Jan 2026 Repare Therapeutics has been acquired by XenoTherapeutics
- 21 Nov 2025 Repare Therapeutics terminates phase I trial in Solid tumours (In adolescents, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in the US and Denmark (PO), due to the sponsor decided to terminate study early (NCT06232408)